UNSPSC 51313309: Tolpropamine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular structure C18H23N.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 1P6C450YET chemically known as benzenepropanamine, n,n,4-trimethyl-.gamma.-phenyl-, hydrochloride (1:1), but more commonly known as tolpropamine hydrochloride, which bears US NIH Compound Identifier 102987. European Medicines Agency schedules Tolpropamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04913MIG.

UNSPSC 51313309 Tolpropamine hydrochloride is a Commodity code that captures pharmaceutical products state and local health agencies procure directly from manufacturers or through cooperative purchasing vehicles. Recent activity shows state and local governments buying generic pharmaceuticals, naloxone and drug-deactivation systems, and over-the-counter products through competitive bidding and cooperative purchasing agreements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving multiple participating states including Oregon). Solicitations require vendors to hold current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), maintain relationships with authorized wholesalers, and meet specific insurance coverage thresholds. Vendors must also certify E-Verify compliance and drug-free workplace status.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs before issuing a formal RFP. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to state and local facilities across participating jurisdictions, with proposals due March 26, 2026; pricing is weighted at 75 percent of the evaluation, and vendors must pay a 3 percent administrative fee on all contract purchases.